RecruitingNCT07265271

Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

Sponsor

City of Hope Medical Center

Enrollment

600 participants

Start Date

Jan 15, 2025

Study Type

OBSERVATIONAL

Conditions

Hepatocellular Carcinoma (HCC)

Summary

Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a multi-omics-based liquid biopsy assay, especially focusing on ncRNAs (e.g. tsRNA, miRNA, circRNA, lncRNA, etc.) for accurate detection of early-stage HCC.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study aims to develop a blood-based test for early detection of liver cancer (hepatocellular carcinoma) by analyzing tiny RNA molecules called tsRNAs that circulate freely in the blood. It is a biomarker discovery study — researchers are collecting blood samples, not testing a new treatment. **You may be eligible if...** - You have been diagnosed with hepatocellular carcinoma (a type of liver cancer), confirmed by tissue biopsy - You have had standard diagnostic and staging procedures done - A blood sample was collected before you received any curative treatment - For control group participants: you do not have cancer **You may NOT be eligible if...** - You are unable or unwilling to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.